Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity was posted on June 8, 2012. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Software licenses and maintenance support services

Closed
FDA-SOL-1103216Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

Agency

N/A

NAICS

511210 - Software Publishers

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts

Full Description

Show more
The U.S. Food and Drug Administration intends to negotiate and award on a sole source basis to PPD Development, LP, under the authority 41 U.S.C. 253(c) (1), as set forth in FAR 6.302-1. This acquisition is to provide Table Trans software licenses and maintenance support currently being used for the FDA's Adverse Event Data from AERS. The Food and Drug Administration (FDA) requires TableTrans software which is a data mapping tool that can help with converting data to a more usable format. Modifying data to a usable format has been a major initiative at the FDA. Much of the data submitted to FDA requires reformatting to be used in analytic tools. TableTrans is used to prepare the Adverse Event Data from AERS for use in Empirical Signal, a data mining tool. This tool can also be used to modify pre-clinical and clinical trial data. The period of performance for the annual maintenance is one year. This requirement is currently being provided by PPD Development, LP and there are no resellers or 3rd parties that can provide these licenses. There are no other sources that can provide maintenance for this software. The purpose of this requirement is to provide additional licenses and software support for the FDA. The software must support data transformations as a sequence of basic steps. Specifically, the software should posses the following salient characteristics: - Specify, execute and automatically document complex data transformations - Specify and extract transformed data interactively or in batch mode to files or databases - Provides a wide range of built-in transformation operators and database functions to minimize programming - Visual Programming o Simplify data management and retrieval tasks through visual programming. o Transform data visually, step-by-step o Include visual transformations diagrams in order to facilitate explanation and modification - Selection from many data transformation operators - Provide SQL functionality without programming - Automatic documentation - 21 CFR compliant Additionally, the software vendor shall provide support, including installation support, updates and technical support during regular business hours. Technical support should be available through telephone, or email during regular business hours. The NAICS code is 511210 and the size standard is $25M. This notice is not a request for competitive quotations. However, any firm that believes it can meet these requirements may submit a written response via email to Veronica Dhaness at the email address below by 12:00 PM Eastern Time on June 15, 2012. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to comply with the above requirement. Information received will be considered; however, a determination by the Government not to compete the proposed acquisition based on responses to this notice is solely within the discretion of the Government. If no responses are received, the FDA will proceed with the sole source award to PPD Development, LP, 929 N Front St., Wilmington, NC 28401. The anticipated award date of this order is around June 25, 2012. No collect calls will be accepted. If you have any questions regarding this announcement, please contact veronica.dhaness@fda.hhs.gov.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS